Chronic Diseases and Urban Health incorporating the TB case-control platform
Lead Research Organisation:
London School of Hygiene & Tropical Medicine
Department Name: UNLISTED
Abstract
Changes in environment, nutrition, infrastructure, and epidemics has had profound impacts on the health of people worldwide. The impact in developing countries is even more pronounced due to lack of adequate health systems. The TB platform has demonstrated the importance of active cases finding, monitoring, follow up and analysis of exposed contacts on the overall health of the population. The evolution of the platform to chronic diseases and urban health will allow us to upscale this work and better evaluate the requirements for disease monitoring and prevention in The Gambia. The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks for the Unit. Information will be collected on environment, socio-economic status and risk factors related to lifestyle and will therefore work as a ‘targeted’ urban health surveillance system.
Technical Summary
The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks. It will evolve from the current TB Case Contact (TBCC) platform and include existing patients’ cohorts, e.g. rheumatic heart disease, who will be visited at least once a year to collect information on (among others) environment, socio-economic status and risk factors related to lifestyle. This platform will work as a ‘targeted’ urban health surveillance system and possibly develop into an urban HDSS.
The TB case-contact platform was established at MRC in 2001 and allows multi-disciplinary analysis of TB across the spectrum of infection and disease with over 2000 TB cases and 10000 close contacts enrolled to date. The platform has generated over 120 publications including epidemiological, clinical, microbiological, and immunological investigations and is currently recruiting participants for studies on post-TB lung health, a phase III TB vaccine trial, diagnostic and prognostic analysis of TB cases and their contacts and community screening of sub-clinical TB.
The CD&UH platform will include the existing cohorts of TB, chronic liver disease and rheumatic heart disease patients and patients with other chronic diseases such as hypertension, diabetes, and chronic respiratory diseases, e.g. asthma. Patients and their families will be visited at least once a year and data on demographic variables, environment, socio-economic status and risk factors related to lifestyle, health seeking behaviour, etc. will be collected. For each patient in the cohort, we will identify three neighbouring families for which we will collect the same information.
The TB case-contact platform was established at MRC in 2001 and allows multi-disciplinary analysis of TB across the spectrum of infection and disease with over 2000 TB cases and 10000 close contacts enrolled to date. The platform has generated over 120 publications including epidemiological, clinical, microbiological, and immunological investigations and is currently recruiting participants for studies on post-TB lung health, a phase III TB vaccine trial, diagnostic and prognostic analysis of TB cases and their contacts and community screening of sub-clinical TB.
The CD&UH platform will include the existing cohorts of TB, chronic liver disease and rheumatic heart disease patients and patients with other chronic diseases such as hypertension, diabetes, and chronic respiratory diseases, e.g. asthma. Patients and their families will be visited at least once a year and data on demographic variables, environment, socio-economic status and risk factors related to lifestyle, health seeking behaviour, etc. will be collected. For each patient in the cohort, we will identify three neighbouring families for which we will collect the same information.
Publications
Cornell TR
(2023)
Histoplasma Seropositivity in TB Patients in The Gambia: Evidence to Drive Research on a High-Priority Fungal Pathogen.
in Open forum infectious diseases
Cottam A
(2023)
The impact of prior SARS-CoV-2 infection on host inflammatory cytokine profiles in patients with TB or other respiratory diseases.
in Frontiers in immunology
Devoid I
(2022)
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Goletti D
(2023)
The Challenge of Tuberculosis in the 21st Century
Jacobs R
(2022)
Concurrent evaluation of cytokines improves the accuracy of antibodies against Mycobacterium tuberculosis antigens in the diagnosis of active tuberculosis.
in Tuberculosis (Edinburgh, Scotland)
Jobe D
(2022)
Gene expression in TB disease measured from the periphery is different from the site of infection.
in Tuberculosis (Edinburgh, Scotland)
Koeppel L
(2023)
Diagnostic performance of host protein signatures as a triage test for active pulmonary TB.
in Journal of clinical microbiology
Nwongbouwoh Muefong C
(2022)
Neutrophils Contribute to Severity of Tuberculosis Pathology and Recovery From Lung Damage Pre- and Posttreatment.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Related Projects
Project Reference | Relationship | Related To | Start | End | Award Value |
---|---|---|---|---|---|
MC_UU_00031/1 | 01/04/2022 | 31/03/2027 | £2,493,333 | ||
MC_UU_00031/2 | Transfer | MC_UU_00031/1 | 01/04/2022 | 31/03/2027 | £2,493,333 |
MC_UU_00031/3 | Transfer | MC_UU_00031/2 | 01/04/2022 | 31/03/2027 | £2,493,333 |
MC_UU_00031/4 | Transfer | MC_UU_00031/3 | 01/04/2022 | 31/03/2027 | £2,015,400 |
MC_UU_00031/5 | Transfer | MC_UU_00031/4 | 01/04/2022 | 31/03/2027 | £2,015,400 |
MC_UU_00031/6 | Transfer | MC_UU_00031/5 | 01/04/2022 | 31/03/2027 | £2,015,400 |
MC_UU_00031/7 | Transfer | MC_UU_00031/6 | 01/04/2022 | 31/03/2027 | £2,015,400 |
MC_UU_00031/8 | Transfer | MC_UU_00031/7 | 01/04/2022 | 31/03/2027 | £2,015,400 |
MC_UU_00031/9 | Transfer | MC_UU_00031/8 | 01/04/2022 | 31/03/2027 | £11,247,000 |
Description | M72 Epi study |
Organisation | Gates |
Country | United States |
Sector | Private |
PI Contribution | Site PI for a multi-site epi study |
Collaborator Contribution | Sponsor for the study |
Impact | None yet |
Start Year | 2022 |
Description | TB Sequel II |
Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
Country | Germany |
Sector | Academic/University |
PI Contribution | MRC is one of the clinical sites and Prof Sutherland is the site-PI and work package lead for host immunological analysis |
Collaborator Contribution | LMU is the lead PI institution |
Impact | None yet as the project has only just begun |
Start Year | 2023 |
Description | TBVAC-HORIZON |
Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Site PI |
Collaborator Contribution | 30 other sites contributing to development of novel TB vaccines |
Impact | None to date |
Start Year | 2023 |